Brief: Hansa Biopharma Announces Supportive Data From Treatment With Imlifidase Prior To Administration Of Gene Therapy For Duchenne Muscular Dystrophy

Hansa Biopharma AB

01/08/2025 20:19

Aug 1 (Reuters) - Hansa Biopharma AB HNSA.ST:

HANSA BIOPHARMA ANNOUNCES SUPPORTIVE DATA FROM TREATMENT WITH IMLIFIDASE PRIOR TO THE ADMINISTRATION OF GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY

BASED ON THESE OUTCOMES, HANSA AND SAREPTA WILL DISCUSS APPROPRIATE NEXT STEPS FOR PROGRAM.

SAFETY PROFILE OF IMLIFIDASE WAS IN KEEPING WITH PRIOR EXPERIENCE AND THE TRIAL DID NOT GENERATE ANY NEW SAFETY SIGNALS

HANSA-12 WEEKS AFTER ADMINISTRATION OF GENE THERAPY, PATIENTS IN TRIAL DEMONSTRATED EVIDENCE OF AAV-MEDIATED TRANSDUCTION, EXPRESSION OF MICRO-DYSTROPHIN

Source text: ID:nWkr1lhBGB

Further company coverage: HNSA.ST

 ((Reuters.Briefs@thomsonreuters.com;))